J.P. Hemp Company











Menstrual Health and Cannabinoid Research: Current Evidence — J.P. Hemp Company



Health Topics — Endocrine, Reproductive & Limbic

Menstrual Health and Cannabinoid Research: Current Evidence

Menstrual pain has a documented biological mechanism — and the endocannabinoid system is involved in it. What the research landscape looks like for cannabinoids and menstrual health, and where it stands right now.

Standard Research · Tier 2
Last Reviewed: September 2026
~1900 words
Mixed Evidence Tiers — Preclinical and Limited Observational Human Data
Archival anatomical plate — uterine tissue cross-section with CB1 and CB2 receptor expression in 19th-century engraving style
Uterine ECS receptors reference plate

Procedural Note

Dysmenorrhea and endometriosis are medical conditions managed under gynecologist care. Effective treatments exist for both. This article discusses the biology of menstrual pain and the current state of cannabinoid research in this domain. Nothing here constitutes guidance on managing menstrual pain, endometriosis, or any related condition. People with these conditions should work with their gynecologist on treatment decisions.

Menstrual pain is one of the most common reasons women seek medical care, and one of the most historically undertreated. The biology underlying it — prostaglandin-driven uterine contractions, neurogenic inflammation, central sensitization in endometriosis — overlaps with mechanisms the endocannabinoid system is documented to modulate. The research examining that overlap is real, limited, and worth reading carefully.

Mixed Evidence Tiers — Preclinical and Limited Observational Human Data

The Biology of Menstrual Pain — Two Distinct Conditions

Menstrual pain exists on a spectrum from normal physiological discomfort to severely debilitating pain, and it arises through mechanisms that differ depending on whether a structural cause is present.

Primary dysmenorrhea — menstrual pain without an identifiable structural cause — is driven primarily by prostaglandins, particularly prostaglandin E2 and F2α, released from the endometrial lining as it breaks down during menstruation. Prostaglandins cause uterine smooth muscle to contract, reducing blood flow to the uterus and generating the cramping pain characteristic of primary dysmenorrhea. The same prostaglandins that drive uterine contractions also sensitize pain receptors in the uterus and surrounding tissue, amplifying the pain signal. Systemic prostaglandin release explains the headache, nausea, and gastrointestinal symptoms that frequently accompany severe dysmenorrhea.

Endometriosis — a condition in which endometrial-like tissue grows outside the uterus, most commonly on the ovaries, fallopian tubes, and pelvic peritoneum — involves a substantially more complex pain mechanism. Endometriotic lesions are innervated by sensory nerve fibers, generate their own inflammatory environment, and produce prostaglandins and other pro-inflammatory mediators locally. The condition involves central sensitization — a state in which the central nervous system's pain processing becomes amplified through sustained nociceptive input, lowering the threshold for pain perception broadly. This is why endometriosis pain often extends beyond the menstrual cycle and why it frequently involves comorbid pain conditions including interstitial cystitis and irritable bowel syndrome.

The ECS in Uterine and Endometrial Tissue

The endocannabinoid system is present throughout the female reproductive tract. CB1 and CB2 receptors are expressed in uterine smooth muscle, endometrial epithelial cells, and the sensory nerve fibers innervating uterine tissue. Endocannabinoids — anandamide and 2-AG — are produced locally in endometrial tissue, and their concentrations vary across the menstrual cycle in synchrony with hormonal fluctuations.

ECS in the Female Reproductive Tract — Relevant Mechanisms
Mechanism
Relevance to Menstrual Pain
CB1 in uterine smooth muscle
CB1 activation reduces uterine smooth muscle contractility — the same detrusor-like mechanism documented in the Pagano bladder study, operating in uterine tissue. Endocannabinoids modulate the prostaglandin-driven contractions of primary dysmenorrhea through this pathway. The degree to which exogenous cannabinoids reproduce this effect via oral or sublingual dosing has not been directly studied.
CB2 in endometrial immune cells
The endometrium contains macrophages and other immune cells that drive the local inflammatory environment. CB2 activation in these cells reduces pro-inflammatory cytokine production — including the cytokines that promote prostaglandin synthesis. In endometriosis, where aberrant immune activity sustains the inflammatory environment of ectopic lesions, CB2-mediated immune modulation is mechanistically relevant.
Anandamide and endometriosis
A landmark finding by Sanchez et al. (2016): women with endometriosis show significantly lower peritoneal fluid anandamide concentrations than controls, and reduced CB1 receptor expression in endometriotic lesions compared to normal endometrium. This pattern — reduced ECS tone in the context of a painful inflammatory condition — is consistent with ECS dysfunction contributing to endometriosis pain, though causation vs. consequence has not been established.
Central sensitization and CB1
In endometriosis with central sensitization, CB1 activation in spinal cord dorsal horn neurons reduces the amplified pain signaling characteristic of a sensitized central nervous system. This is the same mechanism documented in the Pain & Inflammation pillar's coverage of cannabinoids and chronic pain — relevant here because endometriosis frequently involves the central sensitization component that makes standard analgesics less effective.

What the Research Has Actually Examined

Key Studies — Cannabinoids, Dysmenorrhea, and Endometriosis

Sanchez et al. (2016) — Anandamide in Endometriosis: Measured anandamide and related endocannabinoids in the peritoneal fluid and endometrial tissue of women with and without endometriosis. Found significantly reduced anandamide in endometriosis patients and reduced CB1 expression in ectopic lesions. This is the foundational evidence for ECS involvement in endometriosis — an observational human finding establishing that ECS tone is altered in the condition, not a trial of any intervention.

Dmitrieva et al. (2010) — CB1 and Uterine Pain (Preclinical): Animal model study demonstrating that CB1 activation reduces uterine hyperalgesia — heightened pain sensitivity — in a rat model of dysmenorrhea. Established the mechanistic basis for CB1-mediated analgesia in uterine tissue. Preclinical only; does not establish effect in humans.

Observational Survey Data — Cannabis Use and Dysmenorrhea: Multiple large surveys of women who use cannabis self-medicinally for menstrual pain have been published, reporting substantial proportions (40–85% across studies) finding cannabis helpful for pain reduction. These surveys are methodologically limited — self-selected populations, retrospective recall, no placebo control, no objective pain measures, and THC-dominant cannabis rather than hemp-derived cannabinoids. They establish that cannabis self-medication for menstrual pain is common and subjectively reported as effective. They do not establish that any specific cannabinoid, dose, or preparation is effective.

Randomized Controlled Trial Data: As of 2026, no published randomized controlled trial has examined CBD, CBG, or hemp-derived cannabinoids specifically for dysmenorrhea or endometriosis. The observational and mechanistic evidence base does not substitute for this missing trial evidence.

CBG Specifically — Direct Statement

No published research has examined CBG specifically for dysmenorrhea, endometriosis, or menstrual pain of any kind as of 2026. CBG's mechanisms — CB2 partial agonism, anti-inflammatory activity, and the PPAR-γ pathway — are relevant to the inflammatory component of endometriosis in the same way they are relevant to other inflammatory conditions documented in the archive. CBG's CB1 partial agonism may be relevant to uterine smooth muscle contractility and central pain sensitization through the same mechanisms documented in preclinical models. These are mechanistic inferences from CBG's pharmacological profile applied to the biology of menstrual pain — not evidence of effect in this specific domain.

Treatment Context — What Women with These Conditions Should Know

Primary dysmenorrhea is effectively treated with NSAIDs — nonsteroidal anti-inflammatory drugs, particularly ibuprofen and naproxen — which reduce prostaglandin synthesis directly. Hormonal contraceptives reduce endometrial prostaglandin production and are the most effective long-term management for primary dysmenorrhea in women for whom they are appropriate. These are evidence-based, well-tolerated treatments with decades of clinical data.

Endometriosis management is more complex, combining hormonal suppression, pain management, and surgical treatment of lesions in refractory cases. The central sensitization component of endometriosis pain often requires multidisciplinary pain management approaches. No cannabinoid preparation has demonstrated efficacy for endometriosis management in a controlled trial, and the archive does not suggest otherwise.

The Honest Evidence Summary

The ECS is mechanistically present and relevant in uterine tissue, endometrial immune function, and the central sensitization pathway implicated in endometriosis pain. The Sanchez observational finding — reduced anandamide in endometriosis — is the most direct human evidence of ECS involvement in this condition and is genuinely informative. Preclinical models establish CB1-mediated uterine analgesia. Survey data documents widespread self-medication with cannabis for menstrual pain.

No randomized controlled trial of CBD, CBG, or hemp-derived cannabinoids for dysmenorrhea or endometriosis exists as of 2026. CBG has no research in this domain specifically. The mechanistic rationale for further investigation is well-founded. The clinical evidence has not yet been generated. Women managing these conditions should do so under gynecologist care using established treatments.

References

  1. Sanchez, A.M., Vigano, P., Ambrosini, G., et al. (2016). The endocannabinoid system in the human female reproductive tract. Human Reproduction Update, 22(4), 444–461.
  2. Dmitrieva, N., Nagabukuro, H., Resuehr, D., et al. (2010). Endocannabinoid involvement in endometriosis. Pain, 151(3), 703–710.
  3. Armour, M., Sinclair, J., Noller, G., et al. (2019). Self-management strategies amongst Australian women with endometriosis: A national online survey. BMC Complementary and Alternative Medicine, 19(1), 17.
  4. Bouaziz, J., Bar On, A., Seidman, D.S., & Soriano, D. (2017). The clinical significance of endocannabinoids in endometriosis pain management. Cannabis and Cannabinoid Research, 2(1), 72–80.
  5. Marinho, A.L.Z., Silvério, M.A.M., & Horta, B.L. (2021). Utilization of cannabis-based products by women with endometriosis: A systematic review. Reproductive Sciences, 28(5), 1294–1302.
  6. Strauss, J.F., & Barbieri, R.L. (Eds.). (2019). Yen and Jaffe's Reproductive Endocrinology (8th ed.). Elsevier. [Prostaglandins and dysmenorrhea chapters.]
  7. Taylor, A.H., Ang, C., Bell, S.C., & Konje, J.C. (2007). The role of the endocannabinoid system in gametogenesis, implantation and early pregnancy. Human Reproduction Update, 13(5), 501–513.
Health Topics — Endocrine, Reproductive & Limbic — Standard Research · Tier 2
Last Reviewed: September 2026

These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.